FcRn Inhibitors

Jan 17, 2025

Affecting around 1 in 200 people, Graves’ disease is the most common cause of an overactive thyroid. More than 12% of the US population will develop a thyroid condition during their lifetime and an estimated 20 million Americans have some form of thyroid disease. As per DelveInsight’s estimates, Graves’ disease...

Jul 15, 2024

Vyvgart enjoying strong commercial uptake whereas RYSTIGGO is preferred for MuSK+ Myasthenia gravis. What do the physicians believe? The neonatal Fc receptor (FcRn) inhibitor market is heating up, with a growing cast of leading contenders such as Argenx, JnJ, and UCB pharma, along with a few early-stage players ...

May 06, 2024

Autoimmune disorders, a group of conditions where the immune system mistakenly attacks healthy cells, affect millions worldwide, often leading to debilitating symptoms and reduced quality of life. Traditional treatments for autoimmune disorders have primarily focused on suppressing the immune system, which can leav...